Roanoke Times Copyright (c) 1995, Landmark Communications, Inc. DATE: TUESDAY, September 21, 1993 TAG: 9309210157 SECTION: NATIONAL/INTERNATIONAL PAGE: A2 EDITION: NEW RIVER VALLEY SOURCE: DATELINE: ROCKVILLE, MD. LENGTH: Short
The drug, marketed under the brand name HIVID by Hoffmann-LaRoche Inc., of Nutley, N.J., had been approved previously used in combination with another AIDS drug.
The committee vote is only a recommendation and final action will have to be taken by the FDA. The agency usually follows the advice of its advisory committees.
The committee also voted to remove HIVID from a conditional approval under which it had been authorized for use in combination with AZT, or zidovudine. It now would get full approval.
If the FDA follows the committee recommendation, HIVID will become the third drug approved for single-drug therapy against AIDS. The others are AZT and ddI, or didanonsine - Associated Press
Memo: shorter version ran in the Metro edition.